Company profile: Seer
1.1 - Company Overview
Company description
- Provider of proteomics tools and solutions, including the Proteograph Product Suite (integrated workflow with instruments, consumables, and software for deep, large-scale proteome analysis); Proteograph Analysis Suite for LC-MS data processing, analysis, and visualization; SP100 Automation Instrument; Proteograph Assay Kit; and Seer Technology Access Center services for proteomics research support.
Products and services
- Proteograph Analysis Suite (PAS): LC-MS-optimized software that processes, analyzes, and visualizes proteomics data, with integrated search engines for data identification and annotation
- Proteograph Product Suite: A modular workflow integrating instruments, consumables, and software to enable deep, large-scale proteome analysis for proteomics research
- SP100 Automation Instrument: A laboratory-grade Seer-branded instrument for automated proteomics workflows in research, including sample preparation and peptide quantification operations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Seer
ChromaCode
HQ: United States
Website
- Description: Provider of HDPCR-based molecular diagnostics and bioinformatics solutions for tumor profiling, minimal residual disease detection, and decentralized disease monitoring, paired with cloud software for automated interpretation, remote analysis, and scalable deployment; offerings include a multiplexed NSCLC panel delivering results in 24 hours with high concordance to NGS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ChromaCode company profile →
Astute Medical
HQ: United States
Website
- Description: Provider of diagnostic solutions for high-risk medical conditions via identification and validation of protein biomarkers, focused on community and hospital-acquired acute conditions needing rapid diagnosis and risk assessment. Products include BIOFIRE FILMARRAY Torch, VITEK MS, VIDAS BRAHMS PCT, and BACT/ALERT VIRTUO.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Astute Medical company profile →
Firefly BioWorks
HQ: United States
Website
- Description: Provider of an open platform that enables industrial, academic, and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation, leveraging its core Optical Liquid Stamping technology developed in MIT’s Chemical Engineering Department.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Firefly BioWorks company profile →
Signal Genetics
HQ: United States
Website
- Description: Provider of innovative molecular diagnostic services that help physicians make better-informed decisions in the care of patients with cancer; a commercial-stage molecular diagnostics company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Signal Genetics company profile →
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rome Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Seer
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Seer
2.2 - Growth funds investing in similar companies to Seer
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Seer
4.2 - Public trading comparable groups for Seer
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →